These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19491038)

  • 1. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats.
    Misaka S; Sato H; Yamauchi Y; Onoue S; Yamada S
    Eur J Pharm Sci; 2009 Jun; 37(3-4):469-76. PubMed ID: 19491038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery.
    Onoue S; Yamamoto K; Kawabata Y; Hirose M; Mizumoto T; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):144-50. PubMed ID: 19703531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats.
    Misaka S; Aoki Y; Karaki S; Kuwahara A; Mizumoto T; Onoue S; Yamada S
    Peptides; 2010 Jan; 31(1):72-8. PubMed ID: 19808073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats.
    Onoue S; Aoki Y; Matsui T; Kojo Y; Misaka S; Mizumoto T; Yamada S
    Int J Pharm; 2011 May; 410(1-2):54-60. PubMed ID: 21419198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
    Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
    Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy.
    Onoue S; Sato H; Kawabata Y; Mizumoto T; Hashimoto N; Yamada S
    J Control Release; 2009 Aug; 138(1):16-23. PubMed ID: 19376169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
    Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
    Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.
    Onoue S; Misaka S; Aoki Y; Karaki S; Kuwahara A; Ohide A; Mizumoto T; Yamada S
    Eur J Pharm Sci; 2010 Nov; 41(3-4):508-14. PubMed ID: 20797433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythritol-based dry powder of glucagon for pulmonary administration.
    Endo K; Amikawa S; Matsumoto A; Sahashi N; Onoue S
    Int J Pharm; 2005 Feb; 290(1-2):63-71. PubMed ID: 15664131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability of DPI formulations for novel neurokinin receptor antagonist.
    Kumon M; Yabe Y; Kasuya Y; Suzuki M; Kusai A; Yonemochi E; Terada K
    Int J Pharm; 2008 May; 356(1-2):102-9. PubMed ID: 18294787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical synthesis and formulation design of a PEGylated vasoactive intestinal peptide derivative with improved metabolic stability.
    Onoue S; Matsui T; Kato M; Mizumoto T; Liu B; Liu L; Karaki S; Kuwahara A; Yamada S
    Eur J Pharm Sci; 2013 Jun; 49(3):382-9. PubMed ID: 23608612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations.
    Hatanaka J; Kimura Y; Lai-Fu Z; Onoue S; Yamada S
    Int J Pharm; 2008 Nov; 363(1-2):112-7. PubMed ID: 18706989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium.
    Gervelas C; Serandour AL; Geiger S; Grillon G; Fritsch P; Taulelle C; Le Gall B; Benech H; Deverre JR; Fattal E; Tsapis N
    J Control Release; 2007 Mar; 118(1):78-86. PubMed ID: 17241685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of a rat model of chronic obstructive pulmonary disease (COPD) induced by sidestream cigarette smoke.
    Zheng H; Liu Y; Huang T; Fang Z; Li G; He S
    Toxicol Lett; 2009 Sep; 189(3):225-34. PubMed ID: 19524650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma/COPD-model rats.
    Onoue S; Sato H; Ogawa K; Kojo Y; Aoki Y; Kawabata Y; Wada K; Mizumoto T; Yamada S
    Eur J Pharm Biopharm; 2012 Jan; 80(1):54-60. PubMed ID: 22008148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.
    Seto Y; Suzuki G; Leung SS; Chan HK; Onoue S
    Pharm Res; 2016 Jun; 33(6):1447-55. PubMed ID: 26975360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
    Onoue S; Matsui T; Kuriyama K; Ogawa K; Kojo Y; Mizumoto T; Karaki S; Kuwahara A; Yamada S
    Peptides; 2012 Jun; 35(2):182-9. PubMed ID: 22484228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21, L17]-VIP-GRR (IK312532).
    Ohmori Y; Maruyama S; Kimura R; Onoue S; Matsumoto A; Endo K; Iwanaga T; Kashimoto K; Yamada S
    Regul Pept; 2004 Dec; 123(1-3):201-7. PubMed ID: 15518913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.